Evolus Inc. (EOLS)
NASDAQ: EOLS
· Real-Time Price · USD
11.76
0.36 (3.16%)
At close: May 01, 2025, 3:01 PM
3.16% (1D)
| Bid | 11.74 |
| Market Cap | 758.17M |
| Revenue (ttm) | 266.27M |
| Net Income (ttm) | -50.42M |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -14.7 |
| Forward PE | 17.3 |
| Analyst | Buy |
| Ask | 11.77 |
| Volume | 358,980 |
| Avg. Volume (20D) | 835,929 |
| Open | 11.40 |
| Previous Close | 11.40 |
| Day's Range | 11.22 - 11.77 |
| 52-Week Range | 8.67 - 17.82 |
| Beta | 0.97 |
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....
Sector Healthcare
IPO Date Feb 8, 2018
Employees 332
Stock Exchange NASDAQ
Ticker Symbol EOLS
Website https://www.evolus.com
Analyst Forecast
According to 5 analyst ratings, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is $23.5, which is an increase of 99.83% from the latest price.
Stock ForecastsNext Earnings Release
Evolus Inc. is scheduled to release its earnings on May 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.47%
Evolus shares are trading higher after the company...
Unlock content with
Pro Subscription
3 months ago
+28.26%
Evolus shares are trading higher after the company announced it expects FDA approval for Evolysse gels within 90 days and is eyeing a Q2 2025 rollout in the US. Additionally, the company reported Q4 and FY24 revenue results and provided FY25 guidance.
